Table 2.

Results of multivariable regression analysis showing the associations between erythrocytosis (strict criteria) and CVD history and mortality, stratified according to the presence of concurrent leuko- and/or thrombocytosis or clonal hematopoiesis

	Unadjusted OR/HR (95% CI)	Adjusted OR/HR (95% CI)
Erythrocytosis*
Thrombosis	2.6 (1.6-4.3)†	1.6 (1.0-2.7)
Stroke	1.8 (0.7-4.9)	0.9 (0.3-2.5)
Myocardial infarction	2.9 (1.7-5.0)†	1.9 (1.1-3.5)†
Composite cardiovascular events	2.8 (2.0-4.0)†	1.8 (1.2-2.6)†
Antithrombotic agents	3.0 (2.2-4.1)†	2.2 (1.5-3.4)†
All-cause mortality	3.6 (2.4-5.4)†	1.7 (1.2-2.6)†
Cardiovascular mortality‡	6.3 (3.1-12.6)†	2.2 (1.0-4.6)†
Erythrocytosis with concurrent leuko- and/or thrombocytosis§
Composite cardiovascular events	1.8 (0.7-4.5)	2.2 (0.8-6.1)
All-cause mortality	1.2 (0.3-3.9)	0.9 (0.2-3.7)
Erythrocytosis with clonal hematopoiesis||
Composite cardiovascular events	3.4 (1.0-11.9)	9.1 (1.2-68.4)†
All-cause mortality	2.1 (0.5-9.3)	1.1 (0.1-8.5)

Adjusted regression models include sex, age, BMI, systolic and diastolic blood pressure, smoking status, medical history of diabetes, number of medications used, androgen drug use, drugs for obstructive airway disease, antihypertensive drug use, family history of cardiovascular disease and low-density lipoprotein cholesterol as covariates. Data are shown as OR/HR and 95% CI.

^*The absence of erythrocytosis was used as reference.

^†P < .05.

^‡Results are based on calculations by the authors using nonpublic microdata from Statistics Netherlands. Under certain conditions, these microdata are accessible for statistical and scientific research. For further information: microdata@cbs.nl.

^§Isolated erythrocytosis was used as reference.

^||The absence of clonal hematopoiesis in individuals with erythrocytosis was used as reference.